Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECISION: ctDNA-guided Treatment Decision-making for HER2-negative Metastatic Breast Cancer
NCT07394218Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in breast cancer (3 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival up to 36 months. Started Dec 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07394218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394218.